161 filings
Page 5 of 9
8-K/A
difbb3yf6fxh kw
20 Aug 20
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
c9im rfgfdnf
7 Aug 20
Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
4:43pm
8-K
rftkyou13m
6 Aug 20
Entry into a Material Definitive Agreement
8:51am
8-K
om17gj4a4ym 9tvsrha
8 Jun 20
Submission of Matters to a Vote of Security Holders
4:46pm
8-K
seks60cetgq7x 1tw
7 May 20
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
12:00am
DEFA14A
3x71g
22 Apr 20
Additional proxy soliciting materials
4:38pm
8-K
aikq76dv53 wxyye
2 Apr 20
Denali Therapeutics Provides Pipeline and Business Update In Response to the COVID-19 Pandemic
4:34pm
S-8
judjgd58
28 Feb 20
Registration of securities for employees
12:00am
8-K
z5sef mzzmr0z
27 Feb 20
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
5:17pm
8-K
be7mq
29 Jan 20
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
4:25pm
424B5
mr2k5nf8r0izdaxaon
29 Jan 20
Prospectus supplement for primary offering
4:24pm
8-K
4brt8r3m 4m8bb
27 Jan 20
Denali Therapeutics Announces Proposed Offering of Common Stock
5:13pm
424B5
e6fzuo2j
27 Jan 20
Prospectus supplement for primary offering
5:12pm
8-K
bx6v 9tezrnlmisqrqf8
14 Jan 20
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results from Its LRRK2 Program for Parkinson’s Disease
9:04am
8-K
feg84
6 Nov 19
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
4:32pm